The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
The World Health Report 2002 - Reducing Risks, Promoting Healthy Life
Not Available, N. A. (2003) · Education for Health: Change in Learning & Practice · doi:10.1080/1357628031000116808 · Cited by 6,046
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Robbins and Cotran Pathologic Basis of Disease
Hoda, S. A., & Hoda, R. S. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa163 · Cited by 3,365
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010
Yang, G., Wang, Y., Zeng, Y., Gao, G. F., Liang, X., Zhou, M., Wan, X., Yu, S., Jiang, Y., Naghavi, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61097-1 · Cited by 1,982
Self-citationInhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Robbins and Cotran Pathologic Basis of Disease
Hoda, S. A., & Hoda, R. S. (2005) · Advances in Anatomic Pathology · doi:10.1097/01.pap.0000155072.86944.7d · Cited by 1,571
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
Patsopoulos, N. A., Evangelou, E., & Ioannidis, J. P. (2008) · International Journal of Epidemiology · doi:10.1093/ije/dyn065 · Cited by 1,138
Expression of Programmed Death 1 Ligands by Murine T Cells and APC
Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D. M., Okumura, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5538 · Cited by 951
Programmed death ligand-1 expression in non-small cell lung cancer
Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V. K., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 755
Konishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H., & Nishimura, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0428 · Cited by 678
Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu242 · Cited by 645
Mu, C.-Y., Huang, J.-A., Chen, Y., Chen, C., & Zhang, X.-G. (2011) · Medical Oncology · doi:10.1007/s12032-010-9515-2 · Cited by 577
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Shi, L., Chen, S., Yang, L., & Li, Y. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-74 · Cited by 307
Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro
Blank, C., Kuball, J., Voelkl, S., Wiendl, H., Becker, B., Walter, B., Majdic, O., Gajewski, T. F., Theobald, M., Andreesen, R., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21775 · Cited by 297
Yang, C.-Y., Lin, M.-W., Chang, Y.-L., Wu, C.-T., & Yang, P.-C. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.018 · Cited by 285
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy
Tsushima, F., Yao, S., Shin, T., Flies, A., Flies, S., Xu, H., Tamada, K., Pardoll, D. M., & Chen, L. (2007) · Blood · doi:10.1182/blood-2006-11-060087 · Cited by 239
Chen, Y.-B., Mu, C.-Y., & Huang, J.-A. (2012) · Tumori Journal · doi:10.1177/030089161209800612 · Cited by 218
Molecular predictive and prognostic markers in non-small-cell lung cancer
Coate, L. E., John, T., Tsao, M.-S., & Shepherd, F. A. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70155-x · Cited by 214
Zhang, Y., Wang, L., li, Y., Pan, Y., Hu, H., Li, H., Luo, X., Ye, T., sun, Y., chen, H., et al. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s59959 · Cited by 213
Merelli, B., Massi, D., Cattaneo, L., & Mandalà, M. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.002 · Cited by 170
Jilaveanu, L. B., Shuch, B., Zito, C. R., Parisi, F., Barr, M., Kluger, Y., Chen, L., & Kluger, H. M. (2014) · Journal of Cancer · doi:10.7150/jca.8167 · Cited by 158
Sun, Z., Aubry, M.-C., Deschamps, C. C., Marks, R. S., Okuno, S. H., Williams, B. A., Sugimura, H., Pankratz, V. S., & Yang, P. (2006) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2005.12.057 · Cited by 148
PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients
Liu, Y., Carlsson, R., Ambjørn, M., Hasan, M., Badn, W., Darabi, A., Siesjö, P., & Issazadeh‐Navikas, S. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5812-12.2013 · Cited by 143
Self-citationZheng, Z., Bu, Z., Liu, X., Zhang, L., Li, Z., Wu, A., Wu, X., Cheng, X., Xing, X., Du, H., et al. (2014) · Chinese Journal of Cancer Research · doi:10.3978/j.issn.1000-9604.2014.02.08 · Cited by 140
Tumor-Induced CD8+ T-Cell Dysfunction in Lung Cancer Patients
Prado-García, H., Romero‐Garcia, S., Aguilar‐Cázares, D., Meneses-Flores, M., & López-González, J. S. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/741741 · Cited by 133
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
Hamid, O., & Carvajal, R. D. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.770836 · Cited by 131
Maine, C. J., Aziz, N. H. A., Chatterjee, J., Hayford, C., Brewig, N., Whilding, L. M., George, A. J. T., & Ghaem‐Maghami, S. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1503-x · Cited by 129
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
Aranda, F., Vacchelli, E., Eggermont, A. M. M., Galon, J., Fridman, W. H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27297 · Cited by 119
Update on Immune Checkpoint Inhibitors in Lung Cancer
Creelan, B. (2014) · Cancer Control · doi:10.1177/107327481402100112 · Cited by 86
Langer, C. J. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000059 · Cited by 78
The current status of targeted therapy for non‐small cell lung cancer
Francis, H., & Solomon, B. (2009) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.02141.x · Cited by 66
B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer
Gettinger, S. N., & Herbst, R. S. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000063 · Cited by 66
Current status of targeted therapy in non small cell lung cancer (NSCLC)
Parums, D. V. (2014) · Drugs of today · doi:10.1358/dot.2014.50.07.2185913 · Cited by 40
Cited by
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Carbognin, L., Pilotto, S., Milella, M., Vaccaro, V., Brunelli, M., Caliò, A., Cuppone, F., Sperduti, I., Giannarelli, D., Chilosi, M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130142 · Cited by 447
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Meng, X., Huang, Z., Teng, F., Xing, L., & Yu, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.001 · Cited by 401
Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
Kim, D. H., Kim, H., Choi, Y. J., Kim, S. Y., Lee, J.-E., Sung, K. J., Sung, Y. H., Pack, C.-G., Jung, M.-K., Han, B., et al. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0295-2 · Cited by 374
Lung Cancer Staging and Prognosis
Woodard, G. A., Jones, K. D., & Jablons, D. M. (2016) · Cancer Treatment and Research · doi:10.1007/978-3-319-40389-2_3 · Cited by 366
Metadata
- Authors
- Wang, A., Wang, H. Y., Liu, Y., Zhao, M. C., Zhang, H. J., Lu, Z. Y., Fang, Y. C., Chen, X. F., & Liu, G. T.
- Venue
- European Journal of Surgical Oncology (EJSO)
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 41
- Issue
- 4
- Pages
- 450-456
- ISSN
- 0748-7983 (ISSN-L)
- OpenAlex
- W2048974336
- Cited by
- 255
- References
- 44
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.